http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2015110114-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-08 |
| filingDate | 2013-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2015110114-A |
| titleOfInvention | ANGIOTENZIN IN TREATMENT OF THE CONDITIONS OF THE BRAIN |
| abstract | 1. A method of treating a brain condition, comprising administering to a subject suffering from or susceptible to a brain condition, an angiotensin peptide (1-7) using an intravenous or subcutaneous route of administration. A method according to claim 1, characterized in that said state of the brain is selected from stroke, vascular dementia and traumatic brain damage. A method according to claim 2, characterized in that said stroke is an ischemic stroke, hemorrhagic stroke, or a combination thereof. A method according to claim 1, characterized in that the administration of the angiotensin peptide (1-7) is not administered intracerebroventricularly. A method according to claim 1, wherein the angiotensin peptide (1-7) is administered by continuous infusion. A method according to claim 1, characterized in that the angiotensin peptide (1-7) is administered three times a month. A method according to claim 1, characterized in that the angiotensin peptide (1-7) is administered twice a month. A method according to claim 1, characterized in that the angiotensin peptide (1-7) is administered once a month. A method according to claim 1, characterized in that the angiotensin peptide (1-7) is administered in an effective dose in the range of from about 1 to 1000 μg / kg / day. A method according to claim 1, characterized in that the angiotensin peptide (1-7) is administered in an effective dose in the range of from about 50 to 500 μg / kg / day. A method according to claim 1, characterized in that the angiotensin peptide (1-7) is administered in an effective dose in the range of from about 1 to 60 μg / kg / day. The method according to claim 1, characterized in that the angiotensin peptide (1-7) contains the amino acid sequence of the natural angiotensin Asp-Arg-Val-Tyr-Ile-His-Pro (SEQ ID NO: 1). The method of claim 1, wherein the angiotensin peptide (1-7) is the functional equivalent of SEQ ID NO: 1.14. The method of claim 13, wherein said |
| priorityDate | 2012-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46878481 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419565115 |
Total number of triples: 17.